Multicentre Evaluation of the Wait-and-see Policy for Complete Responders After Chemoradiotherapy for Rectal Cancer
The aim of this prospective observational cohort study is to provide short and long term oncological and functional outcome data on organ preserving treatment in good responders after a standard indication for neoadjuvant (chemo)radiation for rectal cancer.
• Aged 18 years or older
• Primary rectal cancer (pathologically confirmed)
• Treated with neoadjuvant (chemo)radiotherapy
• Clinical complete response (ycT0N0) to neoadjuvant treatment, as determined clinically (digital rectal examination, endoscopy) and radiologically (diffusion weighted imaging-MRI).
• Informed consent and capability of giving informed consent; before informed consent is obtained the patient will be extensively informed about the fact that 'wait-and-see' instead of conventional surgery is not accepted yet by most physicians and that the risks and benefits from these strategies have not been fully determined yet. These issues will be discussed in the patient information form as well.
• Comprehension of the alternative strategies and risks are clear to the patient (in other words that the patient understands the experimental base of the study).